Next-generation antibody therapies – new study showing you trends, R&D progress, and predicted revenues Where’s the next-generation antibody therapies market heading? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
Our 236-page report provides 126 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharmaceutical market.
Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including: – Dr Edwin Moses, CEO, Ablynx – Tim Van Hauwermeiren , CEO, ArGEN-X – The executive management team at Mersana Therapeutics
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, you see revenue forecasts to 2025 for the following submarkets: • Antibody-drug conjugates (ADCs) • Engineered antibodies • Bispecific antibodies • Antibody fragments and antibody-like proteins (ALPs) • Biosimilar antibodies
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for products How will leading next-generation antibody therapies perform to 2025 at world level? Our study forecasts sales of 7 products, including these brands: • Adcetris • Kadcyla • Gazyva/Gazyvaro • Poteligeo • Removab • Blincyto • Kalbitor
Discover how high revenues can go. You see what’s happening, understanding trends, challenges and opportunities.
Our analysis also breaks the main world forecast into geographical markets.
What are the prospects in the leading regions and countries? In addition to analyses of the overall world market, you discover individual revenue forecasts for 5 regional markets to 2025: • US • EU5 • Asia-Pacific • Latin America • Rest of the World
There will be growth in established pharma markets and in developing countries. Our analyses show that the Asia-Pacific, in particular, will continue to achieve high revenue growth to 2025. Developments worldwide in biosimilar regulation and next-generation antibody development will influence the market.
Leading companies and potential for market growth Overall world revenue for next-generation antibody therapies will reach $2.3bn in 2015, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, investment from Big Pharma and increasing demand for chronic disease treatment will increase sales to 2025.
Our work shows you what organisations hold greatest potential. Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Research and development – assess innovation, trends and possibilities What about R&D – the pipeline for new drugs? You see trends for these areas: • Antibody-drug conjugates (ADCs) • Engineered antibodies • Bispecific antibodies • Antibody fragments and antibody-like proteins (ALPs) • Other progress in next-generation antibody therapy development.
Our study also discusses these agents and technologies, among others: • Site-specific linkers • Glycosylation or glycoengineering • Defucosylation • Amino acid modification • Enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) • Bispecific, trispecific and multi-specific antibodies • Domain fragments • Single-chain variable fragments • Alternative scaffolds: DARPins, anticalins, Affibodies, Fynomers, Affilins, Adnectins and i-bodies • Combination therapies • Other novel antibody platforms
Next-generation antibody therapy R&D is strong in antibody-drug conjugates. Novel products and biobetters with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.
What issues will affect the next-generation antibody therapies industry? Our new report discusses issues and events affecting the next-generation antibody therapies market. You will find discussions, including qualitative analyses: • Approved products indicate a path to market acceptance • Challenges exist with current monoclonal antibody therapies • Big Pharma is investing heavily in next-generation pipelines • Biosimilars may slow growth in the next-generation antibody market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Next-Generation Antibody Therapies Market Forecast 2015-2025: Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies report helps you In summary, our 236-page report gives you the following knowledge: • Revenue forecasts to 2025 for the world next-generation antibody therapies market and 5 product categories – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2025 for the leading 5 regional markets – US, EU5, Asia-Pacific, Latin America and Rest of the World • Predicted revenues of 7 leading drugs to 2025 – see potentials of top products • Review of R&D pipelines – investigate developmental trends and progress • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market • View opinions from our survey, seeing interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the next-generation antibody therapies market and leading companies. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Global Next-Generation Antibody Therapies Market Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Antibodies: An Overview
2.2.1 Monoclonal versus Polyclonal Antibodies
2.2.2 A Brief History of Antibody Drug Development
2.2.3 The Antibody Manufacturing Process
2.2.4 Trends in Antibody Development
2.3 Defining Next-Generation Antibodies
2.3.1 Classification of Next-Generation Antibody Therapies
2.3.2 The Need for Next-Generation Technologies
2.4 Development Trends for Next-Generation Antibodies
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report
3. Next-Generation Antibody Therapies: World Market 2015-2025
3.1 The World Next-Generation Antibody Therapies Market in 2014
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Cancer Diagnostics Market Report 2021-2031
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
Visiongain Publishes Cell-Based Assays Market Report to 2030
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
